Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antimalarial drugs: current status and new developments.

Dharmendar Rathore1, Thomas F McCutchan, Margery Sullivan

  • 1Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Washington Street, Blacksburg, VA 24061, USA.

Expert Opinion on Investigational Drugs
|July 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The kinetics and transmission-blocking dynamics of <i>P. falciparum</i> sexual-stage antibody responses in a six-year cohort of Ugandan children and adults.

Research square·2026
Same author

Effects of an amustaline (S-303)/glutathione pathogen reduction system on the in vitro quality of plasma and platelets in treated whole blood.

Transfusion·2025
Same author

CD47-mediated selective accumulation of mature Ly49h+ NK cells to the brain associates with the pathogenesis of cerebral malaria in mice.

Journal of immunology (Baltimore, Md. : 1950)·2025
Same author

A Highly Sensitive Multiplex Antibody Assay Reduces Window Period for Detection of <i>Babesia microti</i> Infection.

Open forum infectious diseases·2025
Same author

Viability of Plasmodium falciparum parasites in human plasma under different storage conditions.

Vox sanguinis·2024
Same author

Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG).

PLoS neglected tropical diseases·2024

Malaria remains a global health crisis, causing millions of deaths annually. Developing new antimalarial drugs and combination therapies is crucial due to widespread drug resistance.

Area of Science:

  • Tropical Medicine
  • Infectious Diseases
  • Pharmacology

Background:

  • Malaria poses a significant global health threat, particularly in developing nations, causing over a million clinical episodes and 3,000 deaths daily.
  • Despite historical efficacy, antimalarial drugs like chloroquine face widespread resistance, necessitating alternative treatments.
  • Sub-Saharan Africa bears the brunt of malaria mortality, highlighting regional disparities in disease impact.

Purpose of the Study:

  • To provide an overview of current antimalarial chemotherapy options.
  • To discuss ongoing efforts in developing novel antimalarial therapeutics.
  • To explore the potential of combination therapies for malaria control.

Main Methods:

  • Review of existing literature on antimalarial drugs and resistance patterns.

Related Experiment Videos

  • Analysis of recent technological advancements in drug discovery.
  • Examination of strategies for modifying existing antimalarial remedies.

    • Main Results:

    • Artemisinin remains the only globally effective antimalarial drug, but resistance is a growing concern.
    • Emerging resistance to existing antimalarial drugs limits their long-term effectiveness.
    • New drug development and combination therapies are essential for future malaria control.

    Conclusions:

    • There is an urgent need for innovative antimalarial therapeutics and treatment regimens.
    • Leveraging technological advances and adapting existing treatments are key strategies.
    • Combination therapies offer a promising approach to combat drug-resistant malaria.